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Abstract
Background: The ongoing extended spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) pandemic has
led to an increasing carbapenem use, requiring release of guidelines for carbapenem usage in France in late 2010.
We sought to determine factors associated with changes in carbapenem use in intensive care units (ICUs), medical
and surgical wards between 2009 and 2013.
Methods: This ward-level multicentre retrospective study was based on data from French antibiotic and multidrug-
resistant bacteria surveillance networks in healthcare facilities. Antibiotic use was expressed in defined daily doses
per 1000 patient-days. Factors associated with the reduction in carbapenem use (yes/no) over the study period
were determined from random-effects logistic regression model (493 wards nested within 259 healthcare facilities):
ward characteristics (type, size…), ward antibiotic use (initial antibiotic use [i.e., consumption of a given antibiotic in
2009], initial antibiotic prescribing profile [i.e., proportion of a given antibiotic in the overall antibiotic consumption
in 2009] and reduction in the use of a given antibiotic between 2009 and 2013) and regional ESBL-PE incidence
rate in acute care settings in 2011.
Results: Over the study period, carbapenem consumption in ICUs (n= 85), medical (n = 227) and surgical wards (n = 181)
was equal to 73.4, 6.2 and 5.4 defined daily doses per 1000 patient-days, respectively. Release of guidelines was followed
by a significant decrease in carbapenem use within ICUs and medical wards, and a slowdown in use within surgical
wards. The following factors were independently associated with a higher probability of reducing carbapenem
use: location in Eastern France, higher initial carbapenem prescribing profile and reductions in consumption of
fluoroquinolones, glycopeptides and piperacillin/tazobactam. In parallel, factors independently associated with a lower
probability of reducing carbapenem use were ICUs, ward size increase, wards of cancer centres, higher initial third-
generation cephalosporin (3GC) prescribing profile and location in high-risk regions for ESBL-PE.
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Conclusions: Our study suggests that a decrease in 3GCs in the overall antibiotic use and the continuation of
reduction in fluoroquinolone use, could allow reducing carbapenem use, given the well-demonstrated role of 3GCs
and fluoroquinolones in the occurrence of ESBL-PE. Thus, antibiotic stewardship programs should target wards with
higher 3GC prescription proportions to reduce them.
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Background
The ongoing extended spectrum β-lactamase (ESBL)-
producing Enterobacteriaceae (ESBL-PE) pandemic,
mainly Escherichia coli, has led to an increasing use of
carbapenems, which are considered as ‘last-line’ treat-
ment against these multidrug-resistant (MDR) bacteria.
This increasing carbapenem consumption worldwide
[1–3], has accelerated the occurrence and spread of
carbapenemase-producing Enterobacteriaceae (CPE) [4],
which can lead to situations of therapeutic dead end. In
France, the number of CPE cases has been increasing
since 2010, and in an epidemic pattern in some regions
[5]. In addition, more and more cases are no longer re-
lated to a foreign country [6]: from 29% of cases in 2010
to 58% in 2015. Lastly, according to the classification of
the European survey of CPE (EuSCAPE), France is cur-
rently at epidemiological stage 4 of CPE spread [7],
which corresponds to ‘multiple epidemiologically-related
outbreaks occurring in different health districts, suggest-
ing an interregional autochthonous inter-institutional
transmission’. Saving antibiotic resources, particularly
carbapenems, has become a global public health priority
[8, 9], especially since the pipeline of new antibiotics is
drying up [10]. Therefore, French guidelines for carba-
penems have been released in late 2010 to limit their use
and improve the prescribing practices of this antibiotic
class [11]. In French healthcare facilities (HCFs), carba-
penem consumption has undergone a significant rise of
145% between 2000 and 2013 [12]: from 0.014 to 0.033
defined daily doses (DDDs) per 1000 inhabitants and per
day. This high consumption level is mainly observed in
intensive care units (ICUs) [13], although carbapenem
use according to hospital wards has been scarcely stud-
ied. In this study, we sought to evaluate changes in car-
bapenem use in ICUs, medical and surgical wards of
French HCFs between 2009 and 2013, and to determine
factors associated with the reduction in use of this anti-
biotic class.
Methods
Design, setting and study period
This multicentre retrospective study at the ward level
was mainly based on data from the ATB-RAISIN net-
work (RAISIN stands for network for warning, investiga-
tion and surveillance of nosocomial infections), which is
responsible for the surveillance of antibiotic consump-
tion in French HCFs. We included a stable cohort of
ICUs, medical and surgical wards of HCFs that partici-
pated in the surveillance every year from 2009 to 2013
on a voluntary basis. The geographical location of these
HCFs refers to Coordinating Centres for Nosocomial In-
fection Control, distributed in five areas (North, West,
South-west, East and South-east), each including several
administrative regions.
Data collection
The ATB-RAISIN surveillance network retrospectively
collected each year various types of data: (i) ward char-
acteristics (type, size in number of beds, type of HCF
from which it was derived, geographical location, and ac-
tivity, expressed in number of patient-days), and (ii) in-
patient antibiotic use, expressed in DDDs per 1000
patient-days (PD), in accordance to the Anatomical
Therapeutic Chemical-DDD classification from the WHO
[14]. Data on antibiotic use (dispensing data) were retrieved
from pharmacy records, as described elsewhere [15]. Such
data related to all antibiotic prescriptions whatever the
context of treatment initiation (empirical or based on bac-
teriological results). Besides carbapenems (J01DH) and the
overall antibiotic consumption (J01 + P01AB + J04AB02),
the following antibiotics were studied: third-generation
cephalosporins (3GCs, J01DD+ J01DE + J01 DC07), fluoro-
quinolones (J01MA), aminoglycosides (J01G), aminopeni-
cillins ± β-lactamase inhibitors (J01CA01 + 02 + 04 +
J01CR01 + 02), imidazoles (J01XD+ P01AB), glycopeptides
(J01XA), piperacillin/tazobactam (J01CR05) and other po-
tential alternatives to carbapenems for treating ESBL-PE in-
fections (fosfomycin J01XX01, nitrofurantoin J01XE01,
pivmecillinam J01CA08, temocillin J01CA17, tigecycline
J01AA12 and cefoxitin J01 DC01) [16]. Moreover, the
BMR-RAISIN network, which is responsible for the na-
tional surveillance of MDR bacteria in HCFs, provided data
on ESBL-PE in acute care settings aggregated at the level of
French regions. These data allowed taking into account the
regional context in which a given ward operated in terms
of ESBL-PE risk. Data generated from the laboratory, in-
cluding antimicrobial susceptibility test results were only
available for a few HCFs. Therefore, these data could not be
considered in this work.
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Data analysis
Temporal trends in carbapenem use within wards were
explored by calculating two indicators: the relative
change (and its 95% confidence interval [CI]) and the
annual growth rate of this consumption (obtained by
dividing the relative change by the number of years of
the relevant time period). These indicators were com-
puted for various time periods: before the release of
guidelines (2009–10), after the release of guidelines
(2011–13) and over the whole of the study period
(2009–13). These guidelines [11] aimed to specify indi-
cations, at the time, for the four available carbapenem
molecules (doripenem has since been withdrawn from
the French market) with the following rules of good clin-
ical practice: carbapenem prescribing should be limited
to nosocomial infections due to MDR Gram-negative
bacteria, absence of a carbapenem-sparing alternative,
empirical treatment with 48–72 h re-assessment and de-
escalation using carbapenem-sparing regimen and limi-
tation of ertapenem to ESBL-PE urinary tract infections
treatment without alternative. We assumed that these
guidelines, released in late 2010, were gradually imple-
mented from 2011 within French HCFs through their
antibiotic stewardship programs (ASPs) and driven by
their ASP committee, especially the mandatory antibiotic
advisor. To take into account the clustered structure of
data (wards nested within HCFs), a random-effects logis-
tic regression analysis was performed to determine fac-
tors associated with the reduction in carbapenem use.
Indeed, traditional regression techniques, by ignoring
this data structure and possible correlation of data, may
lead to biased statistical inferences [17]. The binary out-
come variable was the reduction in carbapenem use
(yes/no) between 2009 and 2013. Independent variables
were the following:
– ward characteristics;
– ward antibiotic use: initial antibiotic use (i.e.,
consumption of a given antibiotic in 2009), initial
antibiotic prescribing profile (i.e., proportion in
percent of a given antibiotic in the overall antibiotic
consumption in 2009) and reduction in the use of a
given antibiotic (binary variable: yes/no) between
2009 and 2013;
– regional ESBL-PE incidence rate in acute care set-
tings in 2011, which was converted in binary data
with the median as cut-off: a given ward was located
in ‘high-risk region’ or in ‘low-risk region’ for ESBL-PE.
First, a univariable random-effects logistic regression
analysis was carried out to assess crude relationship be-
tween the outcome variable and each independent variable.
Second, to determine factors independently associated with
the outcome, a multivariable random-effects logistic
regression model was built by introducing all independent
variables with a p value of less than 0.20 in univariable ana-
lysis except ‘type of ward’ and ‘initial overall antibiotic use’
that were forced into the model due to a strong presump-
tion of confounding effect. A p value of less than 0.05 was
considered as statistically significant. Analyses were con-
ducted using the software package Stata, version 14.1 (Stata
Corp., College Station, TX, USA).
Results
Ward characteristics
Data on participating wards are presented Table 1. A
total of 493 wards from 259 HCFs (approximately 10%
of French HCFs) were included in this study (85 ICUs,
227 medical wards and 181 surgical wards). These wards
were from general hospitals at 78.8%, 61.2% and 52.5%
for ICUs, medical and surgical wards, respectively.
Trends in antibiotic use
As the overall antibiotic consumption during the study
period (2009–13), carbapenem consumption was higher
in ICUs than in medical and surgical wards (Table 2):
73.4, 6.2 and 5.4 DDD/1000 PD, respectively. Addition-
ally, in terms of initial carbapenem prescribing profile,
data (medians) were the following: 3.8% (range, 0.2 to
14.6%) in ICUs, 0.5% (range, 0 to 6%) in medical wards
and 0.4% (range, 0 to 4%) in surgical wards. Between
2009 and 2013, the overall antibiotic use slightly de-
creased in ICUs (from 1487 to 1479 DDD/1000 PD; −
0.52%) and in medical wards (from 622 to 616 DDD/
1000 PD; − 0.89%), whereas it exhibited a moderate in-
crease in surgical wards (from 592 to 625 DDD/1000
PD; + 5.68%). Regarding carbapenem use over the study
period, relative changes showed an increase across the
three types of wards (Fig. 1): ICUs (+ 5.65%), medical
wards (+ 24.1%) and surgical wards (+ 25.1%). Interest-
ingly, this increase did not affect 201 out of 493 (40.8%)
wards included, in which we observed a reduction in car-
bapenem use: 38.8% (33/85) of ICUs, 41.9% (95/227) of
medical wards and 40.3% (73/181) of surgical wards. Ex-
ploring temporal trends in carbapenem use before the re-
lease of guidelines (2009–10) revealed a statistically
significant increase across the three types of wards (Fig. 1):
ICUs (+ 7.5%), medical wards (+ 23.1%) and surgical wards
(+ 17.8%). The time period after the release of guidelines
(2011–13) was followed by, on the one hand, a trend rever-
sal in carbapenem use in ICUs and medical wards (negative
annual growth rate of consumption: − 2.9% and − 1.6%, re-
spectively) and, on the other hand, a slowdown in this con-
sumption in surgical wards (annual growth rate of
consumption declined from + 17.8% to + 2.7%). We should
also point out that the statistically significant decrease in
carbapenem use after the release of guidelines within ICUs
(− 4.9% [95% CI, − 6.4 to − 3.3]) and medical wards (− 4.6%
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[95% CI, − 5.8 to − 3.4]) was more marked in 2012. By con-
trast, the carbapenem use within surgical wards only dis-
played a downward trend (− 1.3% [95% CI, − 3.2 to + 0.7])
between 2011 and 2012, which did not reach statistical sig-
nificance. As regards other antibiotic use (Table 2), in al-
most all cases where an upward trend was noted over the
five-year study period, this increase was greater in surgical
wards than in ICUs and medical wards (e.g., 3GC use).
Conversely, in case of downward trend recorded, the de-
crease was absent or lesser in surgical wards than in other
wards (e.g., fluoroquinolone use). It should also noteworthy
that initial 3GC prescribing profile medians varied as
follows: 13.3% (range, 6.2 to 28.2%) in ICUs, 8.7% (range,
1.4 to 30.4%) in medical wards and 4.8% (range, 0 to
19.3%) in surgical wards. Moreover, initial fluoroquinolone
prescribing profile medians were: 13.7% (range, 2.6 to
33.3%) in ICUs, 16.6% (range, 5.7 to 32.5%) in medical
wards and 13.1% (range, 2.8 to 33.4%) in surgical wards.
Factors associated with the reduction in carbapenem use
Statistical analysis results are reported in Table 3. Surpris-
ingly, univariable analysis detected no significant differ-
ence in reducing carbapenem use according to ward
characteristics. In contrast, as regards antibiotic use, wards
Table 1 Characteristics of participating hospital wards across France
Characteristic ICU wards, N = 85 Medical wards, N = 227 Surgical wards, N = 181
No. of beds in 2013, median (interquartile range) 12 (9–16) 72 (36–150) 63 (44–99)
Type of HCF
- University hospital 4 (4.7%) 4 (1.8%) 4 (2.2%)
- General hospital 67 (78.8%) 139 (61.2%) 95 (52.5%)
- Private hospital 9 (10.6%) 51 (22.5%) 71 (39.2%)
- Cancer centre 0 6 (2.6%) 6 (3.3%)
- Local hospital 0 17 (7.5%) 0
- Rehabilitation and long-term care facility 0 5 (2.2%) 0
- Military hospital 5 (5.9%) 5 (2.2%) 5 (2.8%)
Geographical area
- North 30 (35.3%) 50 (22%) 45 (24.9%)
- West 9 (10.6%) 25 (11%) 17 (9.4%)
- East 14 (16.5%) 45 (19.8%) 36 (19.9%)
- South-east 12 (14.1%) 33 (14.5%) 31 (17.1%)
- South-west 20 (23.5%) 74 (32.6%) 52 (28.7%)
ICU intensive care unit; HCF type of healthcare facility from which the hospital ward included in the study was derived
Table 2 Use of carbapenems and other antibiotic classes in hospital wards across France, 2009–2013
Antibiotic use, DDDs per 1000 patient-days (RC)a ICU wards, N = 85 Medical wards, N = 227 Surgical wards, N = 181
All antibiotics 1487 (−0.52%) 615 (−0.89%) 607 (+ 5.68%)
Carbapenems 73.4 (+ 5.65%) 6.2 (+ 24.1%) 5.4 (+ 25.1%)
- Imipenem 62.1 (−0.74%) 5.3 (+ 13.9%) 4.2 (+ 27.5%)
- Meropenem 5.3 (+ 285%) 0.36 (+ 195%) 0.23 (+ 109%)
- Ertapenem 4.87 (−20.4%) 0.52 (+ 45.3%) 0.86 (− 13.3%)
- Doripenem 1.17 (−16.7%) 0.04 (+ 208%) 0.06 (+ 1125%)
Aminopenicillins ± β-lactamase inhibitors 417 (−2.86%) 318 (−1.65%) 268 (+ 0.94%)
Piperacillin/tazobactam 90.1 (+ 34.7%) 8.6 (+ 79%) 8 (+ 109%)
Third-generation cephalosporins 205.9 (+ 0.78%) 60.4 (+ 18.9%) 38.1 (+33.2%)
Fluoroquinolones 177.2 (−24.2%) 88.4 (− 21.3%) 75.1 (−13.1%)
Aminoglycosides 106.1 (+3.35%) 12.4 (−6.98%) 25.4 (+ 13.8%)
Glycopeptides 59.6 (−23.2%) 9.8 (−5.1%) 10.3 (+ 23.6%)
Imidazoles 61.9 (−3.93%) 20.2 (+ 20.6%) 39.6 (+ 9.96%)
DDD defined daily dose; ICU intensive care unit; RC relative change (%) between 2009 and 2013
aPooled means in DDDs per 1000 patient-days and relative changes in percent
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that recorded a decline in their overall antibiotic use re-
duced more often their carbapenem use (univariable ana-
lysis, p = 0.003). In multivariable analysis (Table 3), the
following factors were independently associated with a
higher probability of reducing carbapenem use: a geo-
graphical location in Eastern France in comparison with
South-eastern area of the country, a higher initial carba-
penem prescribing profile and the reductions in consump-
tion of fluoroquinolones, glycopeptides and piperacillin/
tazobactam. Furthermore, other factors were independ-
ently associated with a lower probability of reducing car-
bapenem use: ICU wards (vs. medical wards), ward size
increase, wards of cancer centres (vs. wards of general
hospitals), a higher initial 3GC prescribing profile and lo-
cation in a high-risk region for ESBL-PE.
Discussion
Antibiotic use and potential impact of guidelines on
carbapenem use
In comparison with the meta-analysis of Bitterman et al.
[18], our study showed that antibiotic consumption in
ICUs and medical wards was lower in France than in
other countries worldwide: for overall antibiotic use
(1487 vs. 1563 DDD/1000 PD in ICUs and 615 vs. 677
DDD/1000 patient-days in medical wards), as well as for
specific antibiotic classes, including carbapenems (73.4
vs. 109 DDD/1000 PD in ICUs and 6.2 vs. 16 DDD/1000
PD in medical wards). In the current study, the release
of guidelines for carbapenems in late 2010 was followed
by a significant decrease or a slowdown in their usage in
French hospital wards. This finding suggests a potential
Fig. 1 Changes in carbapenem use in hospital wards across France from 2009 to 2013. For each time period (2009–10, 2011–13 and 2009–13), the
relative change and the annual growth rate of carbapenem consumption (in bold) were computed. CI, confidence interval; DDD defined daily dose
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Table 3 Factors associated with the reduction in carbapenem use from random-effects logistic regression model
Variable Univariable analysis Multivariable analysis
OR p OR pa 95% CI
Type of ward (reference: Medical)
ICU 0.94 0.83 0.07 0.005 0.01–0.46
Surgical 0.95 0.81 0.66 0.19 0.35–1.23
Ward size in 2013, per increase of 50 beds 0.90 0.14 0.79 0.02 0.64–0.97
Type of HCF (reference: General hospital)
University hospital 0.42 0.35 0.28 0.25 0.03–2.39
Private hospital 1.06 0.85 0.66 0.28 0.31–1.40
Cancer centre 0.37 0.29 0.09 0.04 0.01–0.88
Local hospital 2.33 0.18 1.19 0.83 0.25–5.54
Rehabilitation and long-term care facility 0.38 0.50 0.24 0.40 0.01–6.59
Military hospital 0.43 0.34 0.18 0.09 0.02–1.28
Geographical area (reference: South-east)
North 1.42 0.42 2.33 0.09 0.88–6.16
West 1.15 0.80 1.09 0.90 0.30–3.94
East 1.93 0.15 3.11 0.03 1.10–8.77
South-west 1.78 0.17 1.57 0.36 0.60–4.12
Antibiotic use, DDDs per 1000 patients-days
Initial CBP useb 1.01 0.01 0.97 0.08 0.95–1.00
Initial prescribing profile of CBPsc 1.22 0.002 3.16 < 0.001 1.88–5.34
Initial 3GC useb 1.00 0.79
Initial prescribing profile of 3GCsc 0.97 0.16 0.89 0.002 0.83–0.96
Reduction in 3GC used 1.34 0.23
Initial FQ useb 1.00 0.25
Initial prescribing profile of FQsc 1.02 0.29
Reduction in FQ used 2.21 0.004 2.3 0.02 1.17–4.53
Initial AG useb 1.00 0.50
Initial prescribing profile of AGsc 0.97 0.44
Reduction in AG used 1.56 0.06 1.13 0.67 0.65–1.96
Initial AP ± BLI useb 1.00 0.83
Initial prescribing profile of AP±BLIsc 1.00 0.99
Reduction in AP ± BLI used 1.10 0.68
Initial Imidazole useb 1.00 0.98
Initial prescribing profile of imidazolesc 0.97 0.45
Reduction in imidazole used 1.65 0.03 1.50 0.15 0.87–2.59
Initial GP useb 1.00 0.95
Initial prescribing profile of GPsc 0.97 0.61
Reduction in GP used 1.83 0.01 1.98 0.02 1.13–3.45
Initial TZP useb 1.00 0.99
Initial prescribing profile of TZPc 0.95 0.33
Reduction in TZP used 4.24 < 0.001 4.02 < 0.001 1.99–8.14
Initial use of other alternatives to CBPsb 1.00 0.88
Initial prescribing profile of other alternatives to CBPsc 1.31 0.25
Reduction in the use of other alternatives to CBPsd 1.07 0.79
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impact of these guidelines on reducing carbapenem use.
Additionally, the magnitude of this impact appears more
marked in ICUs and medical wards than in surgical
wards. These guidelines fitted into the framework of the
French national antibiotic action plans (initiated in 2001,
the latest iteration being 2011–2016) [9] from the
French Ministry of Health. The latter required from each
HCF: (i) implementation of an ASP since 2002 and (ii)
an annual public reporting of the compliance since 2007
with specific antimicrobial stewardship performance in-
dicators, in order to enhance rational antibiotic use [19].
As with carbapenems, trends in the usage of other anti-
biotics suggest that efforts for curbing antibiotic overuse
are more frequently successful in ICUs and medical
wards than in surgical wards. This finding is consistent
with a study carried out at the Zurich University Hos-
pital, which reported a higher proportion of inappropri-
ate therapeutic antibiotic use in surgical wards (49.3%),
in comparison with ICU (32.4%) and medical wards
(32.9%) [20]. Other studies [21, 22] showed in surgeons
a poor adherence to ASP, sometimes even following an
educational intervention program. Some factors specific
to surgeons may explain this fact, such as lack of exten-
sive training in infectious diseases and antibiotic usage
of most surgical training programs [23]. Therefore, a
special effort should be made for surgeons in ASP inter-
ventions that aim at reducing carbapenem use.
Factors modifying the probability of reducing ward-level
carbapenem use
The multivariable analysis identified five factors posi-
tively associated with the reduction in carbapenem use.
First, a geographical location in Eastern France was asso-
ciated with a higher probability of reducing carbapenem
use compared with a location in South-eastern of the
country. This could be a result of specific local situa-
tions. We could cite as an example, the increasing
spread of CPE, in a region previously hit by a major
vancomycin-resistant enterococci outbreak [24], which
may have prompted a better compliance with prudent
carbapenem use to lower selection pressure. All other
things being equal, including initial overall antibiotic
use, a 1% increase in initial carbapenem prescribing pro-
file was associated with more than threefold increase in
the probability of reducing carbapenem use. Such an ob-
servation could be due to the fact that it is probably eas-
ier to reduce carbapenem use within wards with high
proportions of carbapenems in the initial overall anti-
biotic use than within wards that use them sparingly. In-
deed, in these wards with a high initial carbapenem
prescribing profile, there was likely a greater room for
improvement in terms of proper carbapenem use, not-
ably through de-escalation strategies, which are still in-
sufficiently implemented [25]. Lastly, wards, which
reduced their consumptions of fluoroquinolones, glyco-
peptides and piperacillin/tazobactam, reduced more fre-
quently their carbapenem use. Maybe this reflects what
is covered by the positive and significant association be-
tween the reduction in overall antibiotic use and the re-
duction in carbapenem use in univariable analysis. This
association was not significant in multivariable analysis.
Furthermore, about the variable ‘reduction in fluoro-
quinolone use’, this could be also interpreted as a result
of the involvement of fluoroquinolones in the occur-
rence of antibiotic-resistant bacteria [26], including
ESBL-PE. Indeed, the reduction in fluoroquinolone use
decreased the ESBL-PE risk and therefore the recourse
to carbapenems. Moreover, this reduction in fluoro-
quinolone use is probably due to multiple ASP interven-
tions within French HCFs and release of national
guidelines, especially for urinary tract infections [27–29].
Clearly, the decrease in fluoroquinolone use over the
study period has been partly achieved thanks to a shift
of the antibiotic prescribing towards 3GCs and piperacil-
lin/tazobactam, of which consumptions increased while
overall antibiotic use remained almost stable. Besides,
the positive association between the reduction in pipera-
cillin/tazobactam use and the reduction in carbapenem
use was surprising in view of the potential role of pipera-
cillin/tazobactam as a carbapenem-sparing antibiotic. An
Table 3 Factors associated with the reduction in carbapenem use from random-effects logistic regression model (Continued)
Variable Univariable analysis Multivariable analysis
OR p OR pa 95% CI
Initial overall antibiotic useb 1.00 0.72 1.00 0.97 0.99–1.01
Reduction in the overall antibiotic used 2.02 0.003 1.38 0.29 0.76–2.51
Region with high ESBL-PE incidence rate in acute care settingse 0.65 0.12 0.40 0.01 0.19–0.82
OR odds ratio, CI confidence interval, ICU intensive care unit, HCF healthcare facility, DDD defined daily dose, CBP carbapenem, 3GC third-generation cephalosporin, FQ
fluoroquinolone, AG aminoglycoside, AP ± BLI aminopenicillin ± β-lactamase inhibitor, GP glycopeptide, TZP piperacillin/tazobactam. ESBL-PE extended-spectrum
β-lactamase-producing Enterobacteriaceae
aSignificant associations (p < 0.05) from multivariable analysis are highlighted in bold italic
bConsumption of a given antibiotic in 2009
cProportion (%) of a given antibiotic in the total antibiotic consumption in 2009
dReduction in the consumption of a given antibiotic between 2009 and 2013
eData from the French multidrug-resistant bacteria surveillance network; BMR-RAISIN, 2011
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optimistic explanation could be the ‘virtous cycle’ hy-
pothesis, with a global improvement in prescribing,
resulting in a decrease of all previously overprescribed
antibiotics. In parallel, five other factors were negatively
associated with reduction in carbapenem use. ICUs and
wards of cancer centres had probabilities of reducing
carbapenem use which were about 90% lower than those
of medical wards and wards of general hospitals, respect-
ively. Such a finding is consistent, given a higher severity
and a more frequent previous antibiotic exposure in pa-
tients in these acute care settings, leading to a greater
risk for developing severe infections with resistant
Gram-negative bacteria [30]. Therefore, carbapenem
prescribing can be less frequently avoidable. A 50-bed
increase in ward size was associated with a 21% decrease
in the probability of reducing carbapenem use. To ex-
plain this result, we assume that the number of doctors
prescribing antibiotics increases with the ward size. It is
likely that interventions conducted by ASP committees,
which aim at promoting the proper use of carbapenems
are harder to implement within larger wards, especially
since the heterogeneity of antibiotic prescribing is pos-
sibly higher [31]. Lastly, a 1% increase in the initial pre-
scribing profile of 3GCs was associated with 11%
decrease in the probability of reducing carbapenem use,
and this for the same level of initial overall antibiotic
use. Likewise, wards located in high-risk regions for
ESBL-PE exhibited a 60% decrease in the probability of
reducing carbapenem use. The explanation for these two
last findings is to be found in the ESBL-PE risk, which is
promoted by 3GC use [26], and thus leads to more fre-
quent carbapenem use. It should be recalled that 3GC
use remained stable or increased between 2009 and
2013 across the three types of wards. Hence, the reduc-
tion in 3GC use appears as an essential factor in future
ASPs aiming to reduce carbapenem prescribing. To a
lesser extent, this is also the case for the reduction in
fluoroquinolone use, which is already in progress and
must be continued. For example, the retrospective multi-
centre study from Batard et al. [32], regarding emer-
gency department patients treated for community-
acquired pneumonia, revealed that use of 3GCs and
fluoroquinolones was avoidable in 70% and 52% of cases,
respectively. These antibiotics could be replaced with
aminopenicillins ± β-lactamase inhibitors. Furthermore,
recent applications of matrix-assisted laser desorption
ionization–time of flight (MALDI-TOF) mass spectrom-
etry (MS) for rapid detection of antibiotic resistance
offer promising perspectives for optimizing antibiotic
prescribing in clinical practice [33, 34]. In other terms,
MALDI-TOF MS, in addition to being a technology for
pathogen identification, could be a valuable tool for early
therapeutic guidance by allowing for example an early
de-escalation whenever possible. Nevertheless, in all
cases, the issue of adherence to the guidelines is central
to the success of such developments.
Limitations
This ward-level multicentre retrospective study is sub-
ject to various limitations. First, no patient-level con-
founding factor has been taken into account.
Consequently, case-mix and potential ecological bias in-
herent to this type of study could not be controlled. Sec-
ond, associations are suggestive and do not necessarily
imply a cause-effect relationship. Therefore, these find-
ings must be confirmed through randomized controlled
intervention studies exploring joint effects of individual-
and group-level factors. Third, we had no data regarding
ASPs in HCFs enrolled in the study. As a result, we
could not measure the implementation of carbapenem
use guidelines. Fourth, DDD measurement presents
biases mentioned elsewhere [35], including as a metric
to study the impact of antibiotic stewardship. Fifth, no
data was available regarding compliance with infection
prevention and control measures. Indeed, hand hygiene,
barrier precautions and carrier screening, by avoiding
the spread of MDR bacteria, may influence carbapenem
use. Additionally, none information on the occurrence
of MDR bacteria outbreaks within HCFs was available in
this study.
Conclusions
Despite these caveats, our study, carried out on a na-
tional scale, in a large number of hospital wards, sug-
gests that a decrease in 3GC proportion in the overall
antibiotic use, as well as the continuation of the reduc-
tion in fluoroquinolone use, could allow reducing ward-
level carbapenem use. Thus, in their future interven-
tions, ASPs should target not only wards with a higher
carbapenem use, but also those with a higher 3GC pre-
scription proportion to conduct actions focusing on both
3GCs and carbapenems to preserve the effectiveness of
these antibiotics in French HCFs.
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